Investors and industry stakeholders are eagerly awaiting the Drug Enforcement Administration’s (DEA) decision on the potential rescheduling of cannabis, a move that could revolutionize the cannabis industry and provide significant tax relief. The timeline for this crucial decision may hinge on an upcoming Administrative Law Judge (ALJ) hearing set for December 2, 2024, which could impact how swiftly these changes are implemented and the extent of market shifts.
OG Article: here
View our Fair Use Policy: here
Watch the Commentary Here
Cannabis Reform: A Secondary Priority in 2024
During a recent webinar hosted by Zuanic & Associates on September 11, 2024, industry experts discussed the ongoing cannabis rescheduling process in the U.S. Moderated by senior analyst Pablo Zuanic and Anthony Coniglio, CEO of NLCP, the panel featured Kelly Fair, a partner at Dentons, and Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws (NORML). Despite growing support for cannabis policy reform among presidential candidates, the panelists highlighted that it remains a secondary issue for many voters.
Morgan Fox stressed that while rescheduling cannabis is a positive step, NORML's primary objective is full descheduling. Fox argued that descheduling would enable Congress to enact comprehensive cannabis regulations, unlike the rescheduling process, which he believes is susceptible to political delays.
Insights on the ALJ Hearing
The panel focused significantly on the upcoming ALJ hearing, emphasizing its critical role in shaping the rescheduling rule. Kelly Fair explained that individuals interested in speaking at the hearing must apply by September 30, with the final list of speakers expected by November 2024. The hearing will serve as a forum for both proponents and opponents of the rescheduling proposal to present their evidence.
Despite the importance of this hearing, both Fair and Fox noted that the DEA has considerable discretion in determining the scope of the hearing and the final rule. The evidence and testimony presented will be crucial in influencing the DEA's decision, but there is no guarantee the agency will adopt the ALJ's recommendations.
Challenges and Potential Delays
The experts acknowledged potential delays and challenges in the rescheduling process. Fox pointed out that any final ruling is likely to face legal opposition, which could extend the timeline for implementation. Fair added that while the ALJ's recommendations are significant, the DEA is not bound to follow them, adding another layer of uncertainty.
The webinar concluded with a note of cautious optimism. While rescheduling could provide immediate benefits, such as alleviating the 280E tax burden, the path forward remains uncertain due to potential political shifts and judicial hurdles. The panelists agreed that rescheduling is a positive development but emphasized that achieving full descheduling is essential for substantial cannabis reform.
Comments